Sleep Testing for Obstructive Sleep Apnea (OSA) — NCD 330 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 330, the national coverage determination governing Medicare sleep testing for obstructive sleep apnea, with a policy update effective January 9, 2026. Here's what billing teams need to know.

CMS sleep apnea coverage policy under NCD 330 has been updated. This policy covers sleep testing for obstructive sleep apnea (OSA) across four device types — from Type I attended polysomnography to portable monitors. The policy does not list specific CPT or HCPCS codes in the current version. Your billing team needs to map coverage criteria to your charge capture immediately, before claims start hitting payer edits.

Quick-Reference Table

CMS Sleep Apnea Coverage Criteria and Medical Necessity Requirements 2026

The NCD 330 CMS coverage policy has been in place since March 3, 2009, but this 2026 modification matters. It reaffirms — and in some cases tightens the framing of — coverage criteria that many billing teams have been applying inconsistently.

The core medical necessity threshold is consistent across all covered device types: the beneficiary must have clinical signs and symptoms indicative of OSA. That phrase is doing a lot of work in your documentation. If the ordering physician's notes don't explicitly tie the sleep test order to clinical signs and symptoms of OSA, your claim is exposed.

CMS covers four categories of sleep testing under this coverage policy. Each has specific requirements. They are not interchangeable.

Type I PSG (attended, facility-based polysomnography) is covered when performed attended in a sleep lab facility. This is the reference standard. It requires at minimum: EEG, EOG, EMG, heart rate or ECG, airflow, breathing/respiratory effort, and arterial oxygen saturation (SaO2). A technologist must supervise the recording during sleep time and must be able to intervene if needed.

Type II and Type III monitors are covered in both attended and unattended settings, whether inside or outside a sleep lab. Type II devices require at least seven channels — including EEG, EOG, EMG, ECG/heart rate, airflow, respiratory effort, and SaO2 — and can calculate the apnea-hypopnea index (AHI) because they capture sleep staging. Type III devices require at minimum four channels: ventilation or airflow (at least two channels of respiratory movement, or respiratory movement plus airflow), heart rate or ECG, and oxygen saturation.

Type IV devices get coverage only if they measure three or more channels, and one of those channels must be airflow. Type IV devices that measure fewer than three channels, or that measure three or more channels but do not include airflow, are not covered. This is where most claim denials happen with portable monitoring — billing teams sometimes assume any multi-channel device qualifies.

Actigraphy-based devices represent a fourth covered category. These devices must measure at least three channels: actigraphy, oximetry, and peripheral arterial tone. They are covered in both attended and unattended settings.

One thing worth flagging about prior authorization: NCD 330 does not specify a prior authorization requirement at the national level. However, your Medicare Administrative Contractor (MAC) may have a local coverage determination (LCD) that adds prior auth requirements or tightens criteria further. Check your MAC's LCD before assuming NCD 330 alone governs your coverage situation.

Reimbursement is tied directly to the device type used and the setting. Type I PSG in a facility-based sleep lab carries different reimbursement than unattended home sleep testing. If your team is billing a Type III device at a Type I rate, or vice versa, your MAC will catch it.

CMS Sleep Apnea Testing Exclusions and Non-Covered Indications

NCD 330 is explicit: any diagnostic sleep test for OSA that does not fall into the four covered categories above is not covered by Medicare. This is a blanket national non-coverage designation, effective for claims with dates of service on or after March 3, 2009.

The real issue here is Type IV devices. A Type IV device that measures fewer than three channels is not covered. A Type IV device that measures three or more channels but does not include airflow is not covered. This trips up billing teams regularly, especially with newer consumer-grade or hybrid monitoring devices that vendors market as "sleep testing."

Type II and Type III monitors used in attended settings in a sleep lab are covered. But a Type I PSG performed unattended is not covered under the Type I category — it must be attended. Don't let facility constraints blur that line.

Coverage Indications at a Glance

CMS Sleep Apnea Billing Guidelines and Action Items 2026

CPT, HCPCS, and ICD-10 Codes for Sleep Testing Under NCD 330

The Centers for Medicare & Medicaid Services did not include specific CPT, HCPCS Level II, or ICD-10-CM diagnosis codes in the current NCD 330 policy document. This is a known gap in this version of the policy.

For sleep apnea billing, the relevant codes are typically found in your MAC's LCD — not the NCD itself. The LCD will map the covered device types and clinical criteria in NCD 330 to specific billable codes.

What to do: Pull your MAC's LCD for sleep testing immediately. Common MACs with active sleep testing LCDs include CGS Administrators, Novitas Solutions, and Palmetto GBA. Your LCD will specify which CPT codes map to Type I PSG, Type II/III portable monitors, and Type IV devices — and will list covered ICD-10 diagnosis codes for OSA.

Do not rely on this blog post or NCD 330 alone to build your code list. The code-level billing guidelines live at the MAC level, and they vary by region.